Advancing treatments for rare diseases together

October 2015

11Oct

EspeRare presented the “Development of Rimeporide, a sodium-hydrogen exchanger inhibitor, as a therapy for Patients with Duchenne Muscular Dystrophy”  at the 20th International Congress of the World Muscle Society in Brighton from 30th September to 4th October 2015.

Development of Rimeporide, a Sodium-Hydrogen Exchanger (NHE-1) Inhibitor, as a therapy for Patients with Duchenne Muscular DystrophyClick on picture to view

For more information on the WMS Congress click here